Diabetes News

A prediction model factoring in recent hospitalizations, comorbidities and drug exposure may help determine the individual risk for COVID-19 critical care admission and mortality for people with diabetes, according to study data.

Patients aged 75 years and older with chronic kidney disease, type 2 diabetes, hypertension and hyperkalemia had “significant reductions in serum potassium” after treatment with patiromer, according to results of a secondary analysis.

The U.S. Preventive Services Task Force released a draft recommendation that, if adopted, would lower the age to start screening adults with overweight or obesity for prediabetes and type 2 diabetes from 40 to 35 years.

Emmy Award- and Golden Globe-winning actress Debbie Allen is teaming up with the National Kidney Foundation on an education campaign aimed at helping people with type 2 diabetes lower their risk of developing chronic kidney disease.

SGLT2 inhibitors provide limited glycemic management benefits and may not be cost-effective for most people with type 2 diabetes, according to a study published in the Journal of Diabetes and Its Complications.

Adults who routinely engage in a high level of physical activity may be able to reduce their risk for developing type 2 diabetes, even in areas with high air pollution, according to a study published in Diabetologia.

Adding to existing evidence that shows the benefits of canagliflozin for patients with type 2 diabetes, researchers found those with “severely increased” baseline albuminuria experienced the most protective kidney effects.

Adults who were aware of their prediabetes status were more likely than those who were unaware to report a perceived risk for diabetes, data show.

The prevalence of obesity was associated with a significant uptick in incident diabetes among U.S. adults, with a disparate impact among white women, according to data published in the Journal of the American Heart Association.

Adults with type 2 diabetes and overweight or obesity assigned a once-monthly monoclonal antibody infusion experienced a marked decrease in fat mass and gains in muscle vs. those assigned placebo, according to findings from a phase 2 study.